Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Couple renews multi-million dollar commitment to screen newborn babies for SCID disorders

Frustrated with the slow pace of implementation of Newborn Screening for Severe Combined Immune Deficiency (SCID), Vicki and Fred Modell renewed a multi-million dollar commitment to screen every baby born in every state for this life threatening condition, often referred to as "Bubble Boy" disease.

21 Oct 2014

Study reveals that people with stress-related inflammation may suffer from depression

Preexisting differences in the sensitivity of a key part of each individual's immune system to stress confer a greater risk of developing stress-related depression or anxiety, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published October 20 in the Proceedings of the National Academy of Sciences.

21 Oct 2014

SynGen announces relocation of corporate headquarters

SynGen, Inc., a company focused on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has moved its corporate headquarters to a new location in Sacramento, California. The headquarter’s new address is 100 Howe Avenue, Suite 185N, Sacramento, CA 95825-8219. All other contact information, including phone numbers, remains the same.

17 Oct 2014

Cell transplantation treatment may benefit people with spinal cord injury

Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies.

16 Oct 2014

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.

14 Oct 2014

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland.

14 Oct 2014

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

A fundamental theory about how our thymus educates our immune police appears to be wrong, scientists say.

9 Oct 2014

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic.

8 Oct 2014

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.

8 Oct 2014

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).

7 Oct 2014

Researchers identify new technique to find rare stem cells

Deep within the bone marrow resides a type of cells known as mesenchymal stem cells (MSCs). These immature cells can differentiate into cells that produce bone, cartilage, fat, or muscle — a trait that scientists have tried to exploit for tissue repair.

7 Oct 2014

CleveXel Pharma receives license for two new oncology patents

CleveXel Pharma, a highly experienced pharmaceutical developer that conforms fully with global regulatory compliance, today announces that it has been granted a license by the SATT Sud Est, a technology transfer accelerator in South Eastern France (Societe d’Acceleration du Transfert de Technologies Sud Est), to exploit two patents.

7 Oct 2014

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.

6 Oct 2014

SynGen announces securement of additional financing from San Francisco-based life sciences venture capital firm

SynGen, Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that it has secured additional financing from Bay City Capital, LLC, a San Francisco-based life sciences venture capital firm.

6 Oct 2014

New research on barcoding tool that tracks origin of blood cells challenges scientific dogma

A 7-year-project to develop a barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: New data from Harvard Stem Cell Institute scientists at Boston Children's Hospital suggests, surprisingly, that the billions of blood cells that we produce each day are made not by blood stem cells, but rather their less pluripotent descendants, called progenitor cells.

6 Oct 2014

CTRC researcher receives special $1.62 million orphan disease grant from FDA

A researcher at the Cancer Therapy & Research Center is the leader on a study receiving a special $1.62 million orphan disease grant from the Food & Drug Administration.

5 Oct 2014

Placenta-derived cells are safe for MS patients

Patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published today in the journal Multiple Sclerosis and Related Disorders.

1 Oct 2014

Gut microbe in patients may tip doctors about SCID

Many people recognize "the bubble boy" as an unusual character from a "Seinfeld" episode or a John Travolta movie.

30 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

Bone Marrow News and Research

Further Reading

Couple renews multi-million dollar commitment to screen newborn babies for SCID disorders

Study reveals that people with stress-related inflammation may suffer from depression

SynGen announces relocation of corporate headquarters

Cell transplantation treatment may benefit people with spinal cord injury

Imperial researchers plan to test DTP3 drug in multiple myeloma patients

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

C3BS inks preferred access agreement with Mayo Clinic

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

FDA designates NurOwn as Fast Track product for ALS treatment

Researchers identify new technique to find rare stem cells

CleveXel Pharma receives license for two new oncology patents

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

SynGen announces securement of additional financing from San Francisco-based life sciences venture capital firm

New research on barcoding tool that tracks origin of blood cells challenges scientific dogma

CTRC researcher receives special $1.62 million orphan disease grant from FDA

Placenta-derived cells are safe for MS patients

Gut microbe in patients may tip doctors about SCID

Aptose joins Beat AML research collaboration

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News